• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

July 27, 2020
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
Heron Therapeutics Cinvanti (aprepitant) injectable emulsion early hospitalized patients with COVID-19 initiation of phase 2 trial
Inotrem nangibotide critically ill COVID-19 patients with features of systemic inflammation clearance to initiate a phase 2a trial granted by the FDA
PhaseBio PB1046 hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome dosing of first patient in phase 2 trial
Sorrento Therapeutics abivertinib patients with COVID-19 who have moderate to severe pulmonary symptoms clearance to initiate a phase 2 trial granted by the FDA
Sinopharm CNBG and G42 Healthcare inactivated COVID-19 vaccine COVID-19 initiation of phase 3 trial
Access Genetics dba OralDNA Lab OraRisk COVID-19 RT-PCR test SARS-CoV-2 Emergency Use Authorization (EUA) granted by the FDA
Luminex xMAP SARS-CoV-2 Multi-Antigen IgG Assay SARS-CoV-2 EUA granted by the FDA
Other Trials and Actions
Larimar Therapeutics CTI-1601 Friedreich’s ataxia dosing of first patients in third cohort of phase 1 trial
Aravive AVB-500 platinum-resistant ovarian cancer completion of patient dosing in phase 1b trial
Ascentage Pharma APG-115 as a single agent or in combinations Chinese patients with relapsed/refractory acute myeloid leukemia or relapsed/progressed high/very high-risk myelodysplastic syndrome dosing of first patient in Phase 1b trial
Regulus Therapeutics RGLS4326 autosomal dominant polycystic kidney disease completion of patient dosing in phase 1 trial
9 Meters Biopharma NM-002 adults with short bowel syndrome dosing of first patients in Phase 1b/2a trial
BerGenBio bemcentinib recurrent glioblastoma dosing of first patient in phase 1/2 trial
ADC Therapeutics loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma dosing of first patient in phase 2 portion of phase 1/2 trial
Dragonfly Therapeutics DF6002 advanced solid tumors dosing of first patient in phase 1/2 trial
XyloCor Therapeutics XC001 refractory angina dosing of first patients in phase 1/2 trial
AnHeart Therapeutics taletrectinib non-small-cell lung cancer with ROS1 fusion dosing of first patient in phase 2 trial
NovoCure tumor treating fields recurrent glioblastoma enrollment of first patient in phase 2 trial
Terns Pharmaceuticals TERN-101 nonalcoholic steatohepatitis dosing of first patient in phase 2 trial
AzurRX BioPharma MS1819 cystic fibrosis patients with exocrine pancreatic insufficiency initiation of phase 2b trial
AxoGen avance nerve graft digital nerve injuries patient enrollment complete in phase 3 trial
Blue Earth Diagnostics rhPSMA-7.3 (18F), an investigational prostate-specific membrane antigen-targeted radiohybrid PET imaging agent men with suspected prostate cancer recurrence based on elevated PSA following prior therapy dosing of first patients in phase 3 trial
Biohaven Pharma verdiperstat multiple system atrophy patient enrollment complete in phase 3 trial
Springworks Therapeutics nirogacestat adult patients with progressing desmoid tumors patient enrollment complete in phase 3 trial
Talaris Therapeutics FCR001 induction or restoration of immune tolerance in living donor kidney transplant recipients dosing of first patient in phase 3 trial
Denovo Biopahrma DB102 (enzastaurin) newly diagnosed glioblastoma Fast Track designation granted by the FDA
Kiniksa Pharmaceutical rilonacept pericarditis Orphan Drug designation granted by the FDA
Orchard Therapeutics OTL-203 mucopolysaccharidosis type I (MPS-I) Orphan Drug designation and Rare Pediatric Disease designations granted by the FDA
Ambu A/S ambu ascope duodeno endoscopic retrograde cholangio-pancreatography procedure approved by the FDA
Channel Medsystems cerene cryotherapy device heavy menstrual bleeding approved by the FDA
Jazz Pharmaceuticals Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy approved by the FDA
KeraNetics KeraStat cream radiation dermatitis approved by the FDA
MC2 Therapeutics Wynzora cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) plaque psoriasis in adults approved by the FDA
Orthofix Medical Juniortho plating system advanced deformity and trauma reconstruction of the lower extremities in pediatrics approved by the FDA

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing